<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254147</url>
  </required_header>
  <id_info>
    <org_study_id>1321-0022</org_study_id>
    <nct_id>NCT03254147</nct_id>
  </id_info>
  <brief_title>Medical Need of OAC Reversal</brief_title>
  <official_title>Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, observational, claims cohort study to assess, for adult patients
      initiating an oral anticoagulant for NVAF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective, observational, claims cohort study to assess, for adult patients
      initiating an oral anticoagulant for NVAF, the incidence rates of emergency surgery, major
      bleeding due to trauma, and major bleeding due to fracture, overall and stratified by age
      (&lt;64, 65-74, &gt;75). The secondary objective is to estimate the overall and age stratified
      incidence of cardiac tamponade and peri-cardiocentesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">October 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence rates of emergency surgery, major bleeding associated with trauma and fracture</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence rates of pericardial effusion and cardiac tamponade</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>patients prescribed with Oral Anti-Coagulants</arm_group_label>
    <description>warfarin and non-vitamin K dependent oral anti-coagulants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>warfarin</description>
    <arm_group_label>patients prescribed with Oral Anti-Coagulants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran</intervention_name>
    <description>Non-vitamin K dependent oral anti-coagulatns (NOACs)</description>
    <arm_group_label>patients prescribed with Oral Anti-Coagulants</arm_group_label>
    <other_name>PRADAXA, PRAZAXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Non-vitamin K dependent oral anti-coagulatns (NOACs)</description>
    <arm_group_label>patients prescribed with Oral Anti-Coagulants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Non-vitamin K dependent oral anti-coagulatns (NOACs)</description>
    <arm_group_label>patients prescribed with Oral Anti-Coagulants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Non-vitamin K dependent oral anti-coagulatns (NOACs)</description>
    <arm_group_label>patients prescribed with Oral Anti-Coagulants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients with atrial fibrillation contained in the Medical Data Vision (MDV) database
        which is a Japanese, nationwide claims data containing approximately 16 million patients
        cumulatively. The data cut is between March 2011 to June 2016, and the patients in the MDV
        database are those who have visited DPC hospitals (diagnostic procedure combination, a
        lump-sum payment system based on disease diagnosis to be treated similar to
        Medicare/Medicaid in the USA) hospitals which provide acute in-patient, as well as
        outpatient care.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -&gt;18 year old non-valvular atrial fibrillation (NVAF) patients

          -  Prescribed dabigatran, rivaroxaban, apixaban, edoxaban or warfarin

          -  atients with confirmed date of initiation of OACs

          -  Patients with a minimum of 6 months of enrolment data prior to index date

          -  Has an index date between 14th of March 2011 to 30 June, 2016

        Exclusion Criteria:

          -  Patients receiving two or more oral anti-coagulants at the same time at index date

          -  Patients with prescriptions of index treatment in the 6 months prior to index date

          -  Patients without enrolment period of at least six month in the database
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nippon Boehringer Ingelheim Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Coagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

